Literature DB >> 11396960

Advanced glomerulosclerosis is reversible in nephrotic mice.

Y Mizuno-Horikawa1, S Mizuno, S Tamura, T Kurosawa.   

Abstract

Advanced glomerulosclerosis, a common hallmark of chronic renal diseases (CRD) is believed to be irreversible, and it is thought that glomerular hyperfiltration and hypertrophy may participate in its pathogenesis. We demonstrate here that glomerulosclerosis is "reversible" in an animal model. We used nephrotic ICGN (nep/nep) mice which showed a rapid progression of glomerulosclerosis, accompanied by histological findings for glomerular hyperfiltration. It is known that ureter ligation reduces glomerular filtration in ligated kidneys. When ureter ligation was applied to our model, glomerulosclerosis (characterized by myofibroblast hyperplasia and over-accumulated matrix protein) weakened in conjunction with suppressed glomerular hypertrophy. During this process, glomerular myofibroblasts showed apoptotic cell death after unilateral ureter ligation (UUO) treatment. Our results suggest that inhibition of glomerular filtration in sclerotic tufts may cause glomerular remodeling through the modulation of molecular and cellular sclerogenesis. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11396960     DOI: 10.1006/bbrc.2001.4903

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin.

Authors:  Bernhard N Bohnert; Ferruh Artunc
Journal:  J Vis Exp       Date:  2018-05-06       Impact factor: 1.355

2.  Retrobulbar Sinus Injection of Doxorubicin is More Efficient Than Lateral Tail Vein Injection at Inducing Experimental Nephrotic Syndrome in Mice: A Pilot Study.

Authors:  Bernhard N Bohnert; Thomas Dörffel; Sophie Daiminger; Carsten Calaminus; Sandro Aidone; Almuth Falkenau; Antje Semrau; Mai J Le; Franz Iglauer; Ferruh Artunc
Journal:  Lab Anim       Date:  2019-01-24       Impact factor: 2.471

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.